Navigation Links
ThermoGenesis Reports Record Quarterly Revenues of $7.2 Million; Full Year Revenues Increase 31 Percent
Date:9/9/2008

/p>

Condensed Consolidated Statements of Cash Flows

(Unaudited)

Years Ended

June 30,

2008 2007

Cash flows from operating activities:

Net loss ($9,181,000) ($6,776,000)

Adjustments to reconcile net loss to

net cash used in operating activities:

Depreciation and amortization 543,000 549,000

Stock based compensation expense 1,921,000 1,094,000

Accretion of discount on short-term

investments (918,000) (1,257,000)

Loss on sale/retirement of equipment 238,000 31,000

Net change in operating assets

and liabilities:

Accounts receivable (2,750,000) 547,000

Inventories (200,000) (2,309,000)

Other current assets 48,000 47,000

Other assets 51,000 (34,000)

Accounts payable 2,112,000 143,000

Accrued payroll and related expenses 39,000 108,000

Deferred revenue (633,000) (231,000)

Other current liabilities 279,000 326,000

Net cash used in operating activities (8,451,000) (7,762,000)

Cash flows from investing activities:

Purchase of short-term investments (44,336,000) (51,420,000)

Maturities of investments 52,000,000 60,500,000

Capital expenditures (514,000) (621,000)

Net cash provided by investing<
'/>"/>

SOURCE ThermoGenesis Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
2. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
3. ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 2007
4. ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007
5. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2008 Results on February 6, 2008
6. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
7. ThermoGenesis Corp. Announces Voluntary Recall of Selected Lots of AXP Bag Sets
8. ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health
9. ThermoGenesis Names Dr. Mahendra Rao to Board of Directors
10. ThermoGenesis Announces Receipt of CE Mark for MarrowXpress(TM)
11. ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM))
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... April 21, 2015  Scientists from the J. ... organization, published a paper today outlining new synthetic ... called diatoms. The researchers, led by first author ... Philip Weyman , Ph.D., conclude that these ... of diatom genetics and thus facilitate advances in ...
(Date:4/21/2015)... , April 21, 2015 Merrimack Pharmaceuticals, ... from a multi-arm Phase 1 study of MM-141, a ... presented in an oral session by Dr. Mansoor ... Cancer Research Annual Meeting in Philadelphia, PA. ... of MM-141 as a monotherapy and in combination with ...
(Date:4/21/2015)... -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced ... April 23, 4:30 p.m. ET. Participants are invited to ... Investor call information: U.S./ Canada ... (925) 418-7845 Participant Passcode: 32888538 Questions can ... tina.amirkiai@fleishman.com . Access will be provided ...
(Date:4/21/2015)... 21, 2015  Cryoport, Inc. (OTCBB: CYRX) ... logistics solutions for the life sciences industry, ... lines, clinical research organizations, vaccine manufacturers and ... Mark W. Sawicki , Chief Commercial Officer, ... Summit in San Francisco, CA ...
Breaking Biology Technology:Scientists at the J. Craig Venter Institute Publish Paper Outlining Efficient Synthetic Biology Methods to Genetically Engineer Microalgae 2Scientists at the J. Craig Venter Institute Publish Paper Outlining Efficient Synthetic Biology Methods to Genetically Engineer Microalgae 3First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 2First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 3First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 4First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 5Ampio Announces Investor Call on Thursday, April 23, 4:30 p.m. ET 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 3
... Oct. 29 Vical Incorporated,(Nasdaq: VICL ) today ... three months and nine months ended September 30, 2008,before ... conduct a,conference call and webcast to discuss the financial ... on Wednesday, November 5. The call is,open on a ...
... Clearance from ... Development Progress Triggered $1M Milestone Payment from Cook Medical - ... 4:30 p.m. Eastern Time -, REDWOOD CITY, Calif., October 28 ... its fiscal 2009 first quarter ended September 30, 2008., "We had ...
... $490 Million, Up 14 Percent over Third Quarter 2007 ... Sales and Earnings Guidance, Introduces 2009 Adjusted Net ... Oct. 28 Cephalon, Inc. (Nasdaq:,CEPH) today reported third quarter ... for the third quarter of 2007, and at the high,end ...
Cached Biology Technology:Vical Announces News Release and Conference Call Schedule For Third Quarter 2008 Financial Results 2Vical Announces News Release and Conference Call Schedule For Third Quarter 2008 Financial Results 3Cardica Announces Fiscal 2009 First Quarter Financial Results 2Cardica Announces Fiscal 2009 First Quarter Financial Results 3Cardica Announces Fiscal 2009 First Quarter Financial Results 4Cardica Announces Fiscal 2009 First Quarter Financial Results 5Cardica Announces Fiscal 2009 First Quarter Financial Results 6Cephalon Reports Another Strong Quarter 2Cephalon Reports Another Strong Quarter 3Cephalon Reports Another Strong Quarter 4Cephalon Reports Another Strong Quarter 5Cephalon Reports Another Strong Quarter 6Cephalon Reports Another Strong Quarter 7Cephalon Reports Another Strong Quarter 8Cephalon Reports Another Strong Quarter 9Cephalon Reports Another Strong Quarter 10Cephalon Reports Another Strong Quarter 11Cephalon Reports Another Strong Quarter 12Cephalon Reports Another Strong Quarter 13Cephalon Reports Another Strong Quarter 14Cephalon Reports Another Strong Quarter 15Cephalon Reports Another Strong Quarter 16Cephalon Reports Another Strong Quarter 17Cephalon Reports Another Strong Quarter 18Cephalon Reports Another Strong Quarter 19
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/14/2015)... NEW YORK , April 14, 2015 /PRNewswire/ ... Fast IDentity Online (FIDO ® ) Alliance tm ... standards-based specifications. FIDO members commit to share technology ... authentication methods that are interoperable, more secure and ... specifications enable biometric identity verification that protects sensitive ...
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... researchers have discovered a novel molecular mechanism that can ... progression of some cancers. In the March 23 online ... scientists from the University of Montreal explain how they ... of inflammatory cytokines that normally activate the immune system, ...
... diagnosis is critical in treating Lyme disease. However, ... initially misdiagnosed because currently available serological tests have ... of infection. Misdiagnosed patients may go untreated and ... face longer and more invasive treatments, as well ...
... National Renewable Energy Laboratory (NREL) recently convened the ... with a mission to enable securitization of solar ... marketplace. SAPC,s primary efforts center on the ... documents relevant to residential and commercial deployment, and ...
Cached Biology News:University of Montreal researchers discover how drug prevents aging and cancer progression 2Penn Researchers attach Lyme disease antibodies to nanotubes, paving way for diagnostic device 2Penn Researchers attach Lyme disease antibodies to nanotubes, paving way for diagnostic device 3Penn Researchers attach Lyme disease antibodies to nanotubes, paving way for diagnostic device 4NREL assembles industry working group to advance solar securitization 2
5,6 Carboxyfluorescein is conjugated to BSA (bovine serum albumin) protein through amide bonds....
2,4,6-Trinitrophenyl hapten is conjugated to Bovine Serum Albumin protein through lysine by amide bonds....
... Edwards (1996) • Provides key ... immunoassays, including RIA, ELISA and ... the photoluminescent and chemiluminescent labels ... also given on assay design ...
EoProbe Eosinophil Staining Kit, 1 Kit...
Biology Products: